Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

⁃ Diagnosis of one of the following myeloproliferative neoplasms (MPNs):

• Atypical CML (aCML)

• Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),

• Chronic myelomonocytic leukemia (CMML)

• Chronic neutrophilic leukemia (CNL),

• Essential thrombocythemia (ET),

• Juvenile myelomonocytic leukemia (JMML),

• Mastocytosis, MPN unclassifiable

• MPN/MDS unclassifiable,

• Primary myelofibrosis (PMF),

• Post-essential thrombocythemia myelofibrosis (post-ET MF),

• Post-polycythemia vera MF (post-PV MF)

• Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)

Locations
Other Locations
Canada
Princess Margaret Cancer Centre
RECRUITING
Toronto
Contact Information
Primary
Vikas Gupta, MD
vikas.gupta@uhn.ca
416-946-4521
Backup
Jaime O. Claudio, PhD
jclaudio@uhnresearch.ca
416-946-4501
Time Frame
Start Date: 2015-04
Estimated Completion Date: 2027-10-31
Participants
Target number of participants: 5000
Treatments
Patients with a diagnosis of MPN
Patients with a myeloproliferative neoplasm (MPN) diagnosis:~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T
Sponsors
Leads: University Health Network, Toronto

This content was sourced from clinicaltrials.gov